ES2655688T3 - Composiciones terapéuticas para polineuropatía simétrica diabética - Google Patents

Composiciones terapéuticas para polineuropatía simétrica diabética Download PDF

Info

Publication number
ES2655688T3
ES2655688T3 ES11835385.3T ES11835385T ES2655688T3 ES 2655688 T3 ES2655688 T3 ES 2655688T3 ES 11835385 T ES11835385 T ES 11835385T ES 2655688 T3 ES2655688 T3 ES 2655688T3
Authority
ES
Spain
Prior art keywords
approximately
composition
pirenzepine
diabetic
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11835385.3T
Other languages
English (en)
Spanish (es)
Inventor
Paul Fernyhough
Nigel A. Calcutt
Lakshmi Kotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Application granted granted Critical
Publication of ES2655688T3 publication Critical patent/ES2655688T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES11835385.3T 2010-10-25 2011-10-24 Composiciones terapéuticas para polineuropatía simétrica diabética Active ES2655688T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40650210P 2010-10-25 2010-10-25
US406502P 2010-10-25
US201161531803P 2011-09-07 2011-09-07
US201161531803P 2011-09-07
PCT/CA2011/001186 WO2012055018A1 (en) 2010-10-25 2011-10-24 Therapeutic compositions for diabetic symmetrical polyneuropathy

Publications (1)

Publication Number Publication Date
ES2655688T3 true ES2655688T3 (es) 2018-02-21

Family

ID=45993001

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11835385.3T Active ES2655688T3 (es) 2010-10-25 2011-10-24 Composiciones terapéuticas para polineuropatía simétrica diabética
ES17206278T Active ES3016907T3 (en) 2010-10-25 2011-10-24 Therapeutic compositions for diabetic symmetrical polyneuropathy

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17206278T Active ES3016907T3 (en) 2010-10-25 2011-10-24 Therapeutic compositions for diabetic symmetrical polyneuropathy

Country Status (13)

Country Link
US (3) US10307428B2 (enExample)
EP (3) EP4537829A3 (enExample)
CN (1) CN103298473B (enExample)
CA (1) CA2804797C (enExample)
DK (1) DK2632468T3 (enExample)
ES (2) ES2655688T3 (enExample)
HR (1) HRP20250395T1 (enExample)
HU (1) HUE070784T2 (enExample)
NO (1) NO2632468T3 (enExample)
PL (2) PL2632468T3 (enExample)
PT (1) PT2632468T (enExample)
RS (1) RS66691B1 (enExample)
WO (1) WO2012055018A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082845B1 (en) * 2013-12-20 2021-02-17 University Of Manitoba Methods and compositions for treatment of peripheral neuropathies
US9743513B2 (en) 2014-12-26 2017-08-22 Industrial Technology Research Institute Flexible electronic device
MX2021011607A (es) * 2019-03-26 2021-12-10 Winsantor Inc Formulaciones topicas para el tratamiento de neuropatias perifericas.
CN121079085A (zh) * 2023-03-16 2025-12-05 格劳科斯公司 眼科乳膏剂制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
JP2002515514A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの局所送逹のための組成物及び方法
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
MXPA03010655A (es) * 2001-05-25 2007-06-22 Valley Forge Pharmaceuticals I Gel oft??lmico de pirenzepina.
WO2003026585A2 (en) * 2001-09-26 2003-04-03 Lukacsko Alison B Compositions and methods for inhibiting eccrine perspiration in humans
WO2007025613A2 (en) * 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
KR20080071185A (ko) * 2005-11-21 2008-08-01 쉐링-프라우 리미티드 부프레노르핀을 포함하는 약제학적 조성물
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
UA99259C2 (ru) * 2006-06-16 2012-08-10 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080255062A1 (en) * 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
CN101422610A (zh) * 2007-12-04 2009-05-06 袁才蔚 一种化学药复合物制剂及其应用

Also Published As

Publication number Publication date
HRP20250395T1 (hr) 2025-05-23
CN103298473B (zh) 2015-07-29
EP2632468A4 (en) 2014-08-27
CN103298473A (zh) 2013-09-11
EP4537829A3 (en) 2025-06-18
HUE070784T2 (hu) 2025-06-28
EP2632468A1 (en) 2013-09-04
EP2632468B1 (en) 2017-12-13
WO2012055018A1 (en) 2012-05-03
DK2632468T3 (en) 2018-02-12
ES3016907T3 (en) 2025-05-12
EP3363439A3 (en) 2018-12-05
PL2632468T3 (pl) 2018-04-30
EP3363439A2 (en) 2018-08-22
CA2804797A1 (en) 2012-05-03
EP4537829A2 (en) 2025-04-16
PT2632468T (pt) 2018-03-02
RS66691B1 (sr) 2025-05-30
US10307428B2 (en) 2019-06-04
PL3363439T3 (pl) 2025-09-22
NO2632468T3 (enExample) 2018-05-12
US11925649B2 (en) 2024-03-12
US20190046540A1 (en) 2019-02-14
US20130267506A1 (en) 2013-10-10
US20240180922A1 (en) 2024-06-06
EP3363439B1 (en) 2025-01-08
CA2804797C (en) 2014-12-23
EP3363439C0 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
US20240180922A1 (en) Treatments for diabetic neuropathy
US20250090545A1 (en) Methods and compositions for treatment of peripheral neuropathies
US11382900B2 (en) Composition for preventing or treating sleep disorders
KR20220003519A (ko) 말초 신경병증 치료를 위한 국소 제형
KR20230151061A (ko) 연성 항콜린제 유사체를 위한 제제
US8816065B2 (en) Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
RU2543326C2 (ru) Фармацевтическая композиция для лечения зуда кожи
JP2023184678A (ja) 皮膚線維症を処置するための組成物および方法
ITBO20060313A1 (it) Formulazioni farmaceutiche per uso transdermico
TR201802123T4 (tr) Diabetik simetrik polinöropati için tedavi bileşimleri.
CN119730856A (zh) 二异丙基膦酰烷作为局部药物用于治疗眼部疾病
CZ202244A3 (cs) Heterocyklické purinové deriváty cytokininů, jejich použití při hojení ran a farmaceutické kompozice obsahující tyto deriváty
HK40035205A (en) Methods and compositions for treatment of peripheral neuropathies